WNT5B drives osteosarcoma stemness, chemoresistance and metastasis.
Rachel S PerkinsGlenn MurraySarocha SuthonLindsey DavisNicholson B PerkinsLily FletcherAmanda BozziSaylor L SchreiberJianjian LinSteven LaxtonRahul R PillaiAlec J WrightGustavo A Miranda-CarboniSusan A KrumPublished in: Clinical and translational medicine (2024)
WNT5B expression is high in osteosarcoma stem cells leading to increased stem cell proliferation and migration through SOX2. WNT5B expression in stem cells increases rates of osteosarcoma metastasis to the lungs and liver in vivo. The hyaluronic acid degradation enzyme HYAL1 is regulated by WNT5B in osteosarcoma contributing to metastasis. Inhibition of WNT5B with a ROR1 antibody decreases osteosarcoma stemness.